Cargando…

Evaluation of the Sensititre YeastOne and Etest in Comparison with CLSI M38-A2 for Antifungal Susceptibility Testing of Three Azoles, Amphotericin B, Caspofungin, and Anidulafungin, against Aspergillus fumigatus and Other Species, Using New Clinical Breakpoints and Epidemiological Cutoff Values

Aspergillosis is an invasive fungal disease associated with high mortality. Antifungal susceptibility testing (AFST) is receiving increasing consideration for managing patients, as well as for surveilling emerging drug resistance, despite having time-consuming and technically complex reference metho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Melhem, Marcia S. C., Coelho, Vivian C., Fonseca, Claudia A., de Oliveira, Lidiane, Bonfietti, Lucas X., Szeszs, Maria. W., Magri, Marcello M. C., Dorneles, Francine S., Taguchi, Hideaki, Moreira, Daniel V. S., Motta, Adriana L., Batista, Marjorie V., Kamei, Katsuhiko, Shikanai-Yasuda, Maria A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9607534/ https://www.ncbi.nlm.nih.gov/pubmed/36297597 http://dx.doi.org/10.3390/pharmaceutics14102161

Ejemplares similares

Comparison of the Sensititre YeastOne antifungal method with the CLSI M27-A3 reference method to determine the activity of antifungal agents against clinical isolates of Candida spp.
por: ALTINBAŞ, Rabiye, et al.
Publicado: (2020)

Multicenter Italian Study on “In Vitro Activities” of Isavuconazole, Voriconazole, Amphotericin B, and Caspofungin for Aspergillus Species: Comparison between Sensititre(TM) YeastOne(TM) and MIC Test Strip
por: Lo Cascio, Giuliana, et al.
Publicado: (2022)

Identification of Candida species and susceptibility testing with Sensititre YeastOne microdilution panel to 9 antifungal agents
por: Kucukates, Emine, et al.
Publicado: (2016)

Susceptibility testing of Leishmania spp. against amphotericin B and fluconazole using the Sensititre™ YeastOne™ YO9 platform
por: Kariyawasam, Ruwandi, et al.
Publicado: (2019)

Comparison of Two Commercial Colorimetric Broth Microdilution Tests for Candida Susceptibility Testing: Sensititre YeastOne versus MICRONAUT-AM
por: Philips, Sophie, et al.
Publicado: (2021)

Antifungal susceptibility profile of Trichosporon isolates: correlation between CLSI and etest methodologies
por: Lemes, Raquel M.L., et al.
Publicado: (2010)

Overestimation of Amphotericin B Resistance in Candida auris with Sensititre YeastOne Antifungal Susceptibility Testing: a Need for Adjustment for Correct Interpretation
por: Siopi, Maria, et al.
Publicado: (2023)

Evaluation of Inoculum Preparation for Etest and EUCAST Broth Dilution to Detect Anidulafungin Polyresistance in Candida glabrata
por: Knoll, Miriam Alisa, et al.
Publicado: (2022)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature
por: Glöckner, A
Publicado: (2011)

1412. Caspofungin and Anidulafungin Behave as Fungistatic Agents Against Candida auris
por: Dudiuk, Catiana, et al.
Publicado: (2018)

817. Caspofungin versus Anidulafungin in Patients with Candidemia: Retrospective Comparative Study
por: Elajez, Reem, et al.
Publicado: (2023)

Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
por: Kofla, G, et al.
Publicado: (2011)

644. Comparative Evaluation of ETEST® ERV bioMérieux with the CLSI Broth Microdilution Method for Eravacycline MIC Determination
por: Sauvonnet, Veronique, et al.
Publicado: (2019)

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance
por: Cusack, T.P., et al.
Publicado: (2019)

In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates
por: Buil, J B, et al.
Publicado: (2020)

656. Sulbactam-Durlobactam MIC Determination: Comparative Evaluation of the New ETEST(®) SUD to the CLSI 2021 Broth Microdilution Method
por: Sauvonnet, Veronique, et al.
Publicado: (2021)

Comparison of M.I.C.E. and Etest with CLSI Agar Dilution for Antimicrobial Susceptibility Testing against Oxacillin-Resistant Staphylococcus spp
por: Campana, Eloiza H., et al.
Publicado: (2014)

Ceftaroline Susceptibility among Isolates of MRSA: A Comparison of EUCAST and CLSI Breakpoints
por: Sachu, Arun
Publicado: (2023)

In Vitro Interaction and Killing-Kinetics of Amphotericin B Combined with Anidulafungin or Caspofungin against Candida auris
por: Caballero, Unai, et al.
Publicado: (2021)

Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs - review of the literature
por: Wilke, MH
Publicado: (2011)

Comparative assessment of CDS, CLSI disc diffusion and Etest techniques for antimicrobial susceptibility testing of Neisseria gonorrhoeae: a 6-year study
por: Singh, Vikram, et al.
Publicado: (2012)

In vitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest
por: Lovero, Grazia, et al.
Publicado: (2017)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

356. Impact of CLSI Breakpoint Changes on Unit-Specific Combination Antibiograms for Gram-Negative Respiratory Isolates
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
por: Tóth, Zoltán, et al.
Publicado: (2020)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

1599. Clinical Outcomes for Patients Treated with Fluoroquinolones for Bacteremia Caused by Enterobacteriaceae Reclassified as Not Susceptible by Updated CLSI Breakpoints
por: Fleischner, Zachary, et al.
Publicado: (2020)

CLSI announces availability of new CLSI microbiology documents
Publicado: (2007)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Appropriateness of Empirical Fluoroquinolones Therapy in Patients Infected with Escherichia coli, Klebsiella pneumoniae, or Pseudomonas aeruginosa: The Importance of the CLSI Breakpoints Revision
por: Wang, Ying, et al.
Publicado: (2021)

2113. Evaluation of Isavuconazole Activity against Aspergillus fumigatus Causing Invasive Infections Worldwide Using the New CLSI Clinical Breakpoints
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
por: Kovács, Renátó, et al.
Publicado: (2021)

2184. Effect of Adjusted CLSI Breakpoints on Center-wide Fluoroquinolone Susceptibilities for Enterobacteriaceae and Pseudomonas aeruginosa: Is It Time to Restrict Empiric Fluoroquinolone Use?
por: Sansom, Sarah, et al.
Publicado: (2019)

230. Multicenter Assessment of the Accuracy of MIC Results for Colistin with MicroScan Dried Gram Negative MIC Panels using CLSI Breakpoints
por: Riedel, Stefan, et al.
Publicado: (2022)

In Vitro Azole and Amphotericin B Susceptibilities of Malassezia furfur from Bloodstream Infections Using E-Test and CLSI Broth Microdilution Methods
por: Rhimi, Wafa, et al.
Publicado: (2020)

Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan
por: Lee, Ching-Chi, et al.
Publicado: (2019)

2813. Impact of a Recent Change in Tobramycin Breakpoints (CLSI) on the Proportion of Pseudomonas aeruginosa Clinical Isolates that are Multidrug-Resistant: CANWARD, 2016 to 2021
por: Walkty, Andrew, et al.
Publicado: (2023)

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study
por: Sinnollareddy, Mahipal G, et al.
Publicado: (2015)

Lack of Association between YEASTONE Antifungal Susceptibility Tests and Clinical Outcomes of Cryptococcus Meningitis
por: Wu, Ting-Shu, et al.
Publicado: (2023)

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia
por: Auzinger, G, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_gb1ci2btbhak9uatje8su6qa8c